CHARLES RIVER LABORATORIES
CRLNYSETrading Snapshot
- Day Range
- $360.01 β $378.23
- 52-Week Range
- $146.20 β $359.89
- Volume (shares)
- 1,299,353
- Avg Volume (shares)
- β
- Shares Outstanding
- 47.7M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $4.02B
- Last Q Revenue
- $1.00B
- P/E Ratio
- β
- P/S Ratio
- 4.4x
- EPS (TTM)
- $-4.85
- Dividend Yield
- β
- Dilution (1yr)
- β3.8%
CHARLES RIVER LABORATORIES
CRLAbout CHARLES RIVER LABORATORIES
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean

Charles River Leverages Virtual Control Groups in GLP Studies
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.

Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) Director James Foster sold 24,042 shares of the company's stock in a transaction dated Thursday, October 22nd. The shares were sold at an avera

8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC
Evergreen Capital Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commissio

Ariel Fund Q3 2026 Leaders And Laggards
ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's sha